National Cancer Institute--Collaborations in Technology Development

Christina Liu cliu at IC.NET
Wed Apr 26 14:54:28 EST 1995


I thought people would be interested in this announcement
that I found today on NewsPage.  

Best regards,

Christina
******************************************************************************
> [storytop]
>     ------------------------------------------------------------------------
> 
> 
> National Cancer Institute/ Opportunity for a Cooperative Research and
> Development Agreement (CRADA) for the Scientific and Commercial
> Development of Monoclonal Antibodies for the Therapy and/or Diagnosis
> of Cancer
> 
>     ------------------------------------------------------------------------
> 
> 
> Source: The Federal Register
> 
> The Federal Register via NewsPage : DEPARTMENT OF HEALTH AND HUMAN
> SERVICES
> 
> National Institutes of Health, PHS, DHHS.
> 
> National Cancer Institute: Opportunity for a Cooperative Research and
> Development Agreement (CRADA) for the Scientific and Commercia l
> Development of Monoclonal Antibodies for the Therapy and/or Diagnosis
> of Cancer
> 
> ACTION: Advertisement.
> 
> SUMMARY: The Laboratory of Tumor Immunology and Biology (LTIB),
> National Cancer Institute is seeking pharmaceutical or biotechnology
> collaborator(s) which can effectively pursue the scientific and
> commercial development of a panel of monoclonal antibodies generated
> against tumor associated antigens for use in the therapy and/or
> diagnosis of a range of human cancers. The primary focus of these
> collaborations will be the development and commercialization of a
> panel of monoclonal antibodies consisting of two major groups: (A)
> Monoclonal antibodies directed against the pancarcinoma antigen,
> TAG-72. TAG-72 is expressed on a range of human carcinomas including
> colorectal, gastric, pancreatic, ovarian, endometrial, breast,
> non-small cell lung, and prostate. Monoclonal antibody CC49 is the
> prototype monoclonal antibody of this group. Humanized and other
> genetically engineered variants of monoclonal antibody CC49 have
> already been developed. (B) Monoclonal antibodies directed against
> human carcinoembryonic antigen, which is expressed on the following
> carcinomas: colorectal, pancreatic, gastric, non-small cell lung, and
> breast carcinoma. The prototype for this group of monoclonal
> antibodies is COL-1. (C) Additionally, it may likely be a further goal
> of these collaborations to develop novel recombinant forms of these
> monoclonal antibodies.
> 
> It is anticipated that because of the magnitude, diversity, and
> expense of these proposed research projects the collaboration(s) may
> take the form of multiple CRADAs. The collaboration(s) will involve
> all aspects of diagnostic and/or therapeutic development from basic
> scientific inquiry to late stage clinical trials which selected
> sponsor(s) will be required to partially support. The selected
> sponsor(s) will collaborate in the development of one or more of the
> following diagnostic or therapeutic forms of these monoclonal
> antibodies: (1) Radiolabeled monoclonal antibodies (diagnostic
> (oncologic imaging) and/or therapeutics); (2) Drug and/or toxin
> conjugated monoclonal antibodies; (3) Pro-drug conjugated monoclonal
> antibodies; (4) Unconjugated monoclonal antibodies (including
> bifunctional forms).
> 
> Sponsors will be selected based upon their ability to collaborate with
> NCI for the development of any of these therapeutic or diagnostic
> forms in accordance with the corporate role and selection criteria
> outlined below. It is emphasized that selection of a collaborator will
> not be dependent upon an entity's ability to perform the largest
> portion of the research project. Rather, a collaborator will be
> selected based upon the scientific merit and intellectual
> contributions brought to each individual project(s). Potential
> collaborators are, therefore, urged to submit proposals which focus on
> particular area(s) of expertise in a well-organized and precise manner
> which clearly outlines a development and commercialization plan.
> Finally, it is also possible that logical extensions of these research
> protocols may be considered as potential collaborative projects.
> Accordingly, proposals must address the requested criteria and
> protocols, but in addition, may include any additional unique
> development projects relating to the core technology.
> 
> The term of the CRADA(s) is anticipated to be three (3) to five (5)
> years.
> 
> ADDRESSES: Inquiries and proposals regarding this opportunity should
> be addressed to either Michael Christini or Mark Noel (Tel
> #301-496-0477, Fax #301-402-2117), Office of Technology Development,
> National Cancer Institute, Building 31, Room 4A49, NIH, 9000 Rockville
> Pike, Bethesda, MD 20892.
> 
> DATES: Proposals must be received at the above address by 5 p.m. June
> 26, 1995.
> 
> [04-25-95 at 18:20 EDT, Counterpoint Publishing]
> 
>     ------------------------------------------------------------------------
> 
> Feedback |Main |Index |Map |SurfNews |Copyright 1995 |Individual, Inc.
> |





More information about the Diagnost mailing list